| Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy LM Kaminskas, VM McLeod, GM Ryan, BD Kelly, JM Haynes, ... Journal of Controlled Release 183, 18-26, 2014 | 204 | 2014 |
| A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems LM Kaminskas, VM McLeod, BD Kelly, G Sberna, BJ Boyd, M Williamson, ... Nanomedicine: Nanotechnology, Biology and Medicine 8 (1), 103-111, 2012 | 194 | 2012 |
| Pharmacokinetics and Tumor Disposition of PEGylated, Methotrexate Conjugated Poly-l-lysine Dendrimers LM Kaminskas, BD Kelly, VM McLeod, BJ Boyd, GY Krippner, ED Williams, ... Molecular pharmaceutics 6 (4), 1190-1204, 2009 | 170 | 2009 |
| Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation LM Kaminskas, VM McLeod, CJH Porter, BJ Boyd Molecular pharmaceutics 9 (3), 355-373, 2012 | 157 | 2012 |
| PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats LM Kaminskas, J Kota, VM McLeod, BD Kelly, P Karellas, CJH Porter Journal of Controlled Release 140 (2), 108-116, 2009 | 155 | 2009 |
| Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker LM Kaminskas, BD Kelly, VM McLeod, G Sberna, DJ Owen, BJ Boyd, ... Journal of controlled release 152 (2), 241-248, 2011 | 147 | 2011 |
| The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer SJ Vervoort, SA Welsh, JR Devlin, E Barbieri, DA Knight, S Offley, ... Cell 184 (12), 3143-3162. e32, 2021 | 108 | 2021 |
| Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse … LM Kaminskas, VM McLeod, BD Kelly, C Cullinane, G Sberna, ... Molecular pharmaceutics 9 (3), 422-432, 2012 | 83 | 2012 |
| PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer … LM Kaminskas, DB Ascher, VM McLeod, MJ Herold, CP Le, EK Sloan, ... Journal of controlled release 168 (2), 200-208, 2013 | 80 | 2013 |
| Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance LM Kaminskas, VM Mcleod, CJH Porter, BJ Boyd Journal of pharmaceutical sciences 100 (11), 5069-5077, 2011 | 80 | 2011 |
| Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers LM Kaminskas, BD Kelly, VM McLeod, G Sberna, BJ Boyd, DJ Owen, ... Molecular pharmaceutics 8 (2), 338-349, 2011 | 73 | 2011 |
| Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous … LM Kaminskas, VM McLeod, DB Ascher, GM Ryan, S Jones, JM Haynes, ... Molecular pharmaceutics 12 (2), 432-443, 2015 | 59 | 2015 |
| Reducing dendrimer generation and PEG chain length increases drug release and promotes anticancer activity of PEGylated polylysine dendrimers conjugated with doxorubicin via a … D Mehta, N Leong, VM McLeod, BD Kelly, R Pathak, DJ Owen, ... Molecular Pharmaceutics 15 (10), 4568-4576, 2018 | 44 | 2018 |
| PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance … LJ Chan, JB Bulitta, DB Ascher, JM Haynes, VM McLeod, CJH Porter, ... Molecular pharmaceutics 12 (3), 794-809, 2015 | 40 | 2015 |
| Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers S Haque, VM McLeod, S Jones, S Fung, M Whittaker, M McIntosh, ... European Journal of Pharmaceutics and Biopharmaceutics 119, 408-418, 2017 | 32 | 2017 |
| Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration VM Mcleod, LJ Chan, GM Ryan, CJH Porter, LM Kaminskas Journal of Pharmaceutical Sciences 104 (4), 1421-1430, 2015 | 30 | 2015 |
| Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with … GM Ryan, VM McLeod, D Mehta, BD Kelly, PC Stanislawski, DJ Owen, ... Nanomedicine: Nanotechnology, Biology and Medicine 13 (8), 2485-2494, 2017 | 25 | 2017 |
| A comparison of the pharmacokinetics and pulmonary lymphatic exposure of a generation 4 PEGylated dendrimer following intravenous and aerosol administration to rats and sheep GM Ryan, RJ Bischof, P Enkhbaatar, VM McLeod, LJ Chan, SA Jones, ... Pharmaceutical research 33, 510-525, 2016 | 25 | 2016 |
| Androgen receptor antagonism accelerates disease onset in the SOD1G93A mouse model of amyotrophic lateral sclerosis VM McLeod, CL Lau, MDF Chiam, TW Rupasinghe, U Roessner, ... British Journal of Pharmacology 176 (13), 2111-2130, 2019 | 23 | 2019 |
| The pharmacokinetics and biodistribution of a 64 kDa PolyPEG star polymer after subcutaneous and pulmonary administration to rats SY Khor, J Hu, VM McLeod, JF Quinn, CJH Porter, MR Whittaker, ... Journal of Pharmaceutical Sciences 105 (1), 293-300, 2016 | 21 | 2016 |
